A Phase 1 interventional study of BMS-986435 in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-19.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics following a single oral dose of BMS-986435 in healthy adult Chinese participants.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986435
Drug: BMS-986435
Specified dose on specified days
Also known as: MYK-224
Maximum observed concentration (Cmax)
Time frame: Up to Day 30
Time of maximum observed concentration (Tmax)
Time frame: Up to Day 30
Area under the concentration time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))
Time frame: Up to Day 30
Number of participants with Adverse Events
Time frame: From date of written consent up to 28 days post last dose
Number of participants with Serious Adverse Events
Time frame: From date of written consent up to 28 days post last dose
Number of participants with AEs leading to discontinuation
Time frame: From date of written consent up to 28 days post last dose
Number of participants with vital sign abnormalities
Time frame: Up to Day 31
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to Day 31
Number of participants with echocardiogram abnormalities
Time frame: Up to Day 30
Number of participants with physical examination abnormalities
Time frame: Up to Day 31
Number of participants with clinical laboratory abnormalities
Time frame: Up to Day 31
Echocardiographic measures of cardiac systolic function: left ventricular ejection fraction (LVEF)
Time frame: Up to Day 30
Echocardiographic measures of cardiac systolic function: left ventricular outflow tract velocity time integral (LVOT-VTI)
Time frame: Up to Day 30
Echocardiographic measures of cardiac systolic function: left ventricular fractional shortening (LVFS)
Time frame: Up to Day 30
Echocardiographic measures of cardiac systolic function: left ventricular global longitudinal strain (LV GLS)
Time frame: Up to Day 30
Echocardiographic measures of cardiac systolic function: left ventricle stroke volume (LVSV)
Time frame: Up to Day 30
Echocardiographic measures of cardiac diastolic function: lateral early diastolic mitral annular velocity (e')
Time frame: Up to Day 30
Echocardiographic measures of cardiac diastolic function: septal e'
Time frame: Up to Day 30
Echocardiographic measures of cardiac diastolic function: early diastolic mitral inflow velocity to early diastolic mitral annular velocity (E/e')
Time frame: Up to Day 30
Echocardiographic measures of cardiac diastolic function: early diastolic mitral inflow velocity to late diastolic mitral inflow velocity ratio (E/A ratio)
Time frame: Up to Day 30
Echocardiographic measures of cardiac structure: LV mass index
Time frame: Up to Day 30
Echocardiographic measures of cardiac structure: LV atrial volume index
Time frame: Up to Day 30
Echocardiographic measures of cardiac structure: interventricular septal thickness
Time frame: Up to Day 30
Echocardiographic measures of cardiac structure: posterior wall thickness
Time frame: Up to Day 30
Echocardiographic measures of cardiac structure: LV end diastolic volume
Time frame: Up to Day 30
Echocardiographic measures of cardiac structure: LV end systolic volume
Time frame: Up to Day 30
Echocardiographic measures of cardiac structure: LV end systolic volume index
Time frame: Up to Day 30
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · www.bms.com
Ran from Jun 2024 to primary completion in Oct 2024, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delocamten